Evidence of extensive cellular immune response after SARS-CoV-2 vaccination in ocrelizumab-treated patients with multiple sclerosis
Abstract Background Patients with multiple sclerosis receiving ocrelizumab-treatment are in desperate need of a protection against SARS-CoV-2 infection. Methods In this study, Euroimmun semi-quantitative Anti-SARS-CoV-2 IgG for detection of humoral response and ELISpot assays for detection of SARS-C...
Guardado en:
Autores principales: | Mosche Pompsch, Neslinur Fisenkci, Peter A. Horn, Markus Kraemer, Monika Lindemann |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
BMC
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/d35be905bf80480d9a2dc2d9f19feff1 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
New horizons for multiple sclerosis therapeutics: milestones in the development of ocrelizumab
por: Frau J, et al.
Publicado: (2018) -
Graves’ disease with spontaneous resolution following ocrelizumab in primary progressive multiple sclerosis
por: Duarte Diana Borges, et al.
Publicado: (2021) -
COMPLEX EFFECTS OF SALMOZAN MEDICINE AND PROBIOТIC BACTERIA OF LACTOBACILLUS GENUS ON NATURAL RESISTANCE AND ADAPTIVE IMMUNIТY OF EXPERIMENTAL ANIМALS
por: Т. N. Nikolaeva, et al.
Publicado: (2014) -
A Retrospective Analysis of Rituximab Treatment for B Cell Depletion in Different Pediatric Indications
por: Merlin Wennmann, et al.
Publicado: (2021) -
A Framework to Identify Antigen-Expanded T Cell Receptor Clusters Within Complex Repertoires
por: Valentina Ceglia, et al.
Publicado: (2021)